ASX:PAA PharmAust (PAA) Stock Price, News & Analysis → The asset beating inflation by 4x (From Colonial Metals) (Ad) Free PAA Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolume3.27 million shsAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend Yield3.88%Price TargetN/A Stock AnalysisStock Analysis Get PharmAust alerts: Email Address Ad Priority GoldBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentially cancel your money. You see Biden and the Fed have teamed up to create a controllable, traceable, programmable digital currency to replace the dollar...Get your free information kit NOW, before it's too late. About PharmAust Stock (ASX:PAA)PharmAust Limited develops targeted cancer therapeutics for humans and animals in Switzerland, Australia, Sweden, the United States, and internationally. The company develops drug discovery intellectual property for the treatment of various cancers, neurological diseases, and viral infections. Its lead candidate is Monepantel (MPL), a small molecule drug which is in Phase II clinical trials for the treatment of cancer. The company also provides products and services in synthetic and medicinal chemistry to the drug discovery and pharmaceutical industries worldwide. It serves drug discovery and pharmaceutical industries. PharmAust Limited was incorporated in 2000 and is based in Bentley, Australia.Read More Ad Priority GoldBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentially cancel your money. You see Biden and the Fed have teamed up to create a controllable, traceable, programmable digital currency to replace the dollar...Get your free information kit NOW, before it's too late. PAA Stock News HeadlinesApril 10, 2024 | msn.comPharmAust inks approval from Macquarie University for Open-Label MND extension studyMarch 27, 2024 | finance.yahoo.comWe Think PharmAust (ASX:PAA) Can Afford To Drive Business GrowthMay 4, 2024 | Porter & Company (Ad)Elon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.March 14, 2024 | msn.comClosing Bell: ASX a little lower after hosting a Big 4 bank midweek spankMarch 14, 2024 | msn.comPharmAust files groundbreaking MND/ALS clinical data with the FDAMarch 13, 2024 | fool.com.auIf you'd put $30,000 in this ASX biotech stock 4 months ago, you'd have $140,000 nowFebruary 28, 2024 | finance.yahoo.comPharmAust advances monepantel for motor neurone disease towards FDA approvalFebruary 28, 2024 | finanznachrichten.dePharmAust Limited: PharmAust announces positive Phase 1 MEND Study Top-Line Results in MND / ALSMay 4, 2024 | Porter & Company (Ad)Elon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.February 28, 2024 | msn.comPharmAust’s MPL could offer MND/ALS sufferers up to 56.5 months additional life expectancyFebruary 28, 2024 | finance.yahoo.comPharmAust announces positive Phase 1 MEND Study Top-Line Results in MND / ALSFebruary 21, 2024 | msn.comPharmAust forms scientific advisory board to guide next phase of monepantel for treatment of MND/ALSFebruary 16, 2024 | msn.comFDA shows the way for accelerated approval of PharmAust’s monepantel in MNDFebruary 14, 2024 | finance.yahoo.comPharmAust (ASX:PAA) delivers shareholders incredible 42% CAGR over 5 years, surging 11% in the last week aloneFebruary 14, 2024 | msn.comPharmAust extension study begins as analysis shows MND/ALS drug ‘defied the odds’February 10, 2024 | morningstar.comPlains All American Pipeline LP PAAFebruary 1, 2024 | markets.businessinsider.comPlains All American Pipeline L.P.January 30, 2024 | benzinga.comPlains All American Stock (NASDAQ:PAA) Dividends: History, Yield and DatesJanuary 30, 2024 | msn.comPharmAust gets ethics committee green light for open-label MND extension studyJanuary 28, 2024 | msn.comFDA offers PharmAust clear guidance for orphan drug designation approvalJanuary 23, 2024 | morningstar.comPlains All American Pipeline LPJanuary 16, 2024 | msn.comPharmAust partners with US-based Berry Consultants for Phase 2/3 studyJanuary 1, 2024 | msn.comPharmAust just got a pre-IND meeting with the US FDA to kick off ‘24December 21, 2023 | msn.comUp to $1.8m funding from motor neurone disease foundation could be on the table for PharmAustDecember 20, 2023 | msn.comSanta (and ATO) delivers PharmAust $550k cash boost for ChristmasDecember 12, 2023 | msn.comProminent Perth fundie the main backer in PharmAust’s $3.5m cap raiseDecember 2, 2023 | au.finance.yahoo.comPharmAust Limited (ECQ.F)See More Headlines Receive PAA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PharmAust and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolASX:PAA CUSIPN/A CIKN/A Webwww.pharmaust.com Phone61 8 6161 7412FaxN/AEmployees2,020Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)A($0.02) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-7,750,000.00 Net Margins-177.28% Pretax MarginN/A Return on Equity-101.98% Return on Assets-31.99% Debt Debt-to-Equity Ratio26.97 Current Ratio4.55 Quick Ratio2.24 Sales & Book Value Annual Sales$3.71 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow10.50 Book ValueA$0.02 per share Price / BookN/AMiscellaneous Outstanding Shares394,330,000Free FloatN/AMarket CapN/A OptionableNot Optionable Beta1.27 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMr. Sam Michael Wright A.C.I.S. (Age 46)ACIS, AFin, DipAcc, M.A.I.C.D., MAICD, Finance Director, Company Secretary & Non-Executive Director Comp: $138kMs. Fiona MilnerGeneral Manager of Epichem Pty LtdDr. Michael Thurn Ph.D.CEO & DirectorDr. Gary PittHead of ChemistryDr. James RixsonHead of ProductionKey Competitors180 Life SciencesNASDAQ:ATNFW3SBioOTCMKTS:TRSBF45525 (CUR.TO)TSE:CUR60 Degrees PharmaceuticalsNASDAQ:SXTPWAbcamOTCMKTS:ABCZFView All CompetitorsInsidersSam WrightSold 450,000 sharesTotal: $45,000.00 ($0.10/share)Roger AstonBought 3,649,904 shares on 12/15/2023Total: $18,249.52 ($0.01/share)Neville BassettSold 1,750 sharesTotal: $122.50 ($0.07/share)Sam WrightSold 250,000 sharesTotal: $20,000.00 ($0.08/share)Sam WrightBought 50,000 shares on 5/10/2023Total: $4,100.00 ($0.08/share) This page (ASX:PAA) was last updated on 5/4/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldAutomatic Income (from home)Awesomely, LLCCould Your Accounts Be Frozen?Allegiance GoldElon to Transform U.S. Economy? Porter & CompanyUrgent Nvidia WarningAltimetryThe asset beating inflation by 4xColonial MetalsThe A.I. story nobody is telling you (Read ASAP)TradeSmithHave You Seen Elon’s New A.I. Device? (Picture Inside)InvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PharmAust Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
